The GSEA results showed that LST, MSI, TP53 mutation status as well as PARP1 and PARP2 expression, but not TP53 expression or ATM expression predicted an enrichment of the PARPi response gene set in both the CRC cohorts (Table 1 and Table 2). The gene discussed is TP53; the disease is colorectal carcinoma.